18F-FDG PET/CT in Primary AL Hepatic Amyloidosis Associated with Multiple Myeloma

We report here on a rare case of primary AL hepatic amyloidosis associated with multiple myeloma in a 64-year-old woman. The patient was referred for evaluating her progressive jaundice and right upper quadrant pain. ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) showed diffusely and markedly increased ¹⁸F-FDG uptake in the liver. Although there have been several case studies showing positive ¹⁸F-FDG uptake in pulmonary amyloidosis, to the best of our knowledge, the ¹⁸F-FDG PET/CT findings of hepatic amyloidosis or primary hepatic amyloidosis associated with multiple myeloma have not been reported previously.     

Bilateral Tubo-Ovarian Abscess Mimics Ovarian Cancer on MRI and 18F-FDG PET/CT

A 20-year-old woman, who presented with a several-week history of abdominal pain, was referred for magnetic resonance imaging (MRI) and ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) after an ultrasound showed complex cystic masses arising from both ovaries. The MRI and ¹⁸F-FDG PET/CT imaging characteristics of the ovarian masses were strongly suspicious for malignancy, and the masses were surgically removed. Histopathological evaluation revealed a bilateral tubo-ovarian abscess, with no evidence of malignancy. This case highlights a potentially serious pitfall in the evaluation of suspicious pelvic masses by ¹⁸F-FDG PET/CT, whereby a complex bilateral tubo-ovarian abscess may mimic the PET/CT imaging characteristics of an ovarian or pelvic malignancy.     

Pictorial review of <Superscript>18</Superscript>F-FDG PET/CT findings in musculoskeletal lesions

We herein reviewed ¹⁸F-fluoro-2-deoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) findings in a number of musculoskeletal lesions including malignant tumors, benign tumors, and tumor-like lesions with correlations to other radiographic imaging modalities, and described the diversity of the ¹⁸F-FDG PET/CT findings of this entity. Malignant primary musculoskeletal tumors are typically ¹⁸F-FDG avid, whereas low-grade malignant tumors show mild uptake. Benign musculoskeletal tumors generally show a faint uptake of ¹⁸F-FDG, and tumor-like conditions also display various uptake patterns of ¹⁸F-FDG. Although musculoskeletal tumors show various uptakes of ¹⁸F-FDG on PET/CT, its addition to morphological imaging modalities such as CT and MRI is useful for the characterization and differentiation of musculoskeletal lesions.     

Primary Pulmonary Low-Grade Angiosarcoma Characterized by Mismatch between 18F-FDG PET and Dynamic Contrast-Enhanced CT

We report a rare case of primary pulmonary low-grade angiosarcoma on dynamic contrast-enhanced CT and ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT imaging. A 38-year-old, asymptomatic woman was hospitalized because of an abnormality on chest radiography. A dynamic contrast-enhanced chest CT showed a 1.2 cm-sized irregular-margined nodule with strong and persistent enhancement in the right lower lobe. The lesion had low metabolic activity on an ¹⁸F-FDG PET/CT scan. The patient underwent a wedge resection for the lesion, and pathology revealed a primary pulmonary low-grade angiosarcoma.     

Malignant Peritoneal Mesothelioma Masquerades as Peritoneal Metastasis on 18F-FDG PET/CT Scans; a Rare Diagnosis that Should Not Be Missed

Malignant peritoneal mesothelioma (MPM) is a rare but fatal tumor. The clinical presentations and imaging findings are nonspecific and resemble various diseases, including peritoneal metastasis. Imaging findings of MPH on ¹⁸F-¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) are diverse and not well described. We report the two cases of biopsy-proven MPH using ¹⁸F-FDG PET/CT. In our cases, interesting disease patterns—including MPH arising from visceral peritoneal lining of kidney that suffer from polycystic disease and from the parietal peritoneum beneath the appendectomy scar—were presented. One case showed classical metastases localized within the abdominal cavity; while the other case exhibited the rare pattern of extensive multi-organ metastases. By knowing the possible variations and diagnostic pitfalls of ¹⁸F-FDG PET/CT findings in MPM, more accurate interpretation of such mysterious cancer is attainable.     

Primary Malignant Fibrous Histiocytoma in Mediastinum: Imaging with 18F-FDG PET/CT

Malignant fibrous histiocytoma (MFH) is the most common soft tissue tumor which often occurs in the extremities and the retroperitoneum. Primary mediastinal MFH is rare; thus, findings on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) of mediastinal MFH have not been reported yet. We report herein the case of a 64-year-old man who was presented with a superior mediastinal mass. The mass showed intense ¹⁸F-FDG uptake with central metabolic defect on PET/CT. The maximum standardized uptake value was 17.4. After tumor removal via median sternotomy, an MFH of the storiform-pleomorphic type was diagnosed on histopathologic examination. We present the first report of ¹⁸F-FDG PET/CT imaging of MFH in the superior mediastinum.     

Small Cell Carcinoma of the Gallbladder: 18F-FDG PET/CT Imaging Features—A Case Report

The diagnostic role of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) for gallbladder small cell carcinoma has not been reported. A knowledge of the imaging characteristic features of this malignancy can be useful. Here we report a rare case of a patient who had various diagnostic imaging modalities, including ¹⁸F-FDG PET/CT.     

Multicentric Primary Angiosarcoma of Bone Mimicking Metastasis on 18F-FDG PET/CT in a Patient with a History of Sigmoid Colon Cancer: a Case Report

Primary angiosarcoma of the bone (PAB) is a rare and fatal high-grade malignant vascular bone tumor. We report a rare case of multicentric PAB mimicking bone metastasis in a 59-year-old female patient with a history of sigmoid colon cancer. This patient complained of lower back and pelvic pain and presented with multiple osteolytic bone lesions on plain radiography and pelvic computed tomography. First, bone metastasis of sigmoid colon cancer was suspected. However, on the ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) scan, the patient presented unusual multiple hypermetabolic osteolytic bone lesions involving contiguous bones of the lower half of the body. After bone biopsy, these lesions were confirmed to be multicentric PAB. To the best of our knowledge, this is the first case report of an ¹⁸F-FDG PET/CT scan in a patient with multicentric primary bone angiosarcoma.     

Clinical significance of 18F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with 18F-FDG PET/CT and MRI

Objective

L-3-[¹⁸F]-fluoro-α-methyl tyrosine (¹⁸F-FAMT) is an amino acid tracer for positron emission tomography/computed tomography (PET/CT) which specifically transported into cancer cells by L-type amino acid transporter 1 (LAT1). LAT1 overexpression in tumors is significantly correlated with cell proliferation and angiogenesis. ¹⁸F-FAMT PET/CT, fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET/CT and magnetic resonance imaging (MRI) were compared for their diagnostic performance in the detection of bone marrow invasion in patients with oral squamous cell carcinoma (OSCC).

Methods

Twenty-seven patients with OSCC on the upper or lower alveolar ridge underwent staging by MRI, ¹⁸F-FDG PET/CT and ¹⁸F-FAMT PET/CT studies before surgery. Post-surgical pathologic examination was used as the standard to determine the final diagnoses. The possibility of bone marrow invasion on MRI, ¹⁸F-FDG PET/CT and ¹⁸F-FAMT PET/CT were usually graded retrospectively into five-point score. Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated according to the obtained scores.

Results

As the sensitivity of ¹⁸F-FDG PET/CT was highest (100 %) among that of MRI (95 %) and ¹⁸F-FAMT PET/CT (90 %), the specificity of ¹⁸F-FAMT PET/CT was highest (85.7 %) among that of MRI (57 %) and ¹⁸F-FDG PET/CT (14.3 %). The size of pathological tumor was accorded with that detected by ¹⁸F-FAMT PET/CT and was smaller than that detected by ¹⁸F-FDG PET/CT (P < 0.01). Significant difference was not found between ¹⁸F-FAMT PET tumor volume and pathological tumor volume.

Conclusions

¹⁸F-FAMT PET/CT was useful and more specific than MRI or ¹⁸F-FDG PET/CT in the detection of bone marrow invasion of OSCC and may contribute to minimize the extent of resection in oral surgery patient.     

Usefulness of <Superscript>18</Superscript>F-FDG PET/CT to Detect Metastatic Mucinous Adenocarcinoma Within an Inguinal Hernia

Metastatic mucinous adenocarcinoma in an inguinal hernia is a rare disease and the image findings of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) are little known. Here, we introduce a 57-year-old man with metastatic mucinous adenocarcinoma in an inguinal hernia. On initial ¹⁸F-FDG PET/CT, hypermetabolism was observed in mucinous adenocarcinoma of the cecum, and adenocarcinomas of the transverse and ascending colon, respectively. Follow-up ¹⁸F-FDG PET/CT revealed newly developed multiple hypermetabolism in peritoneal seeding masses and nodules in the pelvic cavity and scrotum. Peritoneal carcinomatosis in the right pelvic side wall was extended to the incarcerated peritoneum and mesentery in the right inguinoscrotal hernia.¹⁸F-FDG PET/CT was useful to reveal unexpected peritoneal seeding within the inguinal hernia. Also, this case demonstrated that metastatic mucinous adenocarcinomas had variably intense FDG uptake.     

Update on advances in molecular PET in urological oncology

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[¹⁸F]fluoro-2-deoxy-d-glucose (¹⁸F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of ¹⁸F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. ¹⁸F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.     

Giant Cell Tumor with Secondary Aneurysmal Bone Cyst Shows Heterogeneous Metabolic Pattern on <Superscript>18</Superscript>F-FDG PET/CT: A Case Report

Giant cell tumor (GCT) is a generally benign bone tumor accounting for approximately 5 % of all primary bone neoplasms. Cystic components in GCTs that indicate secondary aneurysmal bone cysts (ABCs) are reported in 14 % of GCTs. Although both of them have been described separately in previous reports that may show considerable fluorodeoxyglucose (FDG) uptake despite their benign nature, the findings of GCT with secondary ABC on ¹⁸F-FDG positron emission tomography/computed tomography (PET/CT) have not been well-known. We report a case of GCT with secondary ABC in a 26-year-old woman. ¹⁸F-FDG PET/CT revealed a heterogeneous hypermetabolic lesion in the left proximal femur with the maximum standardized uptake value of 4.7. The solid components of the tumor showed higher FDG uptake than the cystic components. These observations suggest that the ABC components in GCTs show heterogeneous metabolic patterns on ¹⁸F-FDG PET/CT.     

Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor

We present the case of a male patient with gastrointestinal stromal tumor (GIST) in whom we conducted two (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) studies, the first one prior to beginning the treatment with Glivec and the second after one month of treatment. The first (18)F-FDG PET scan detected multiple FDG avid foci in distal esophagus, liver and in an interaortocava lymph node. The second (18)F-FDG PET showed very good response to therapy, with an almost complete disease remission. After 23 months of follow-up, the early response to treatment detected by (18)F-FDG PET was confirmed. The utility of (18)F-FDG PET in the evaluation of response to treatment in GIST is discussed and compared with CT.     

Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT

A 71-year-old woman with type 2 diabetes mellitus complained of generalized fatigue. A 36-mm tumor in the pancreatic tail was detected with ultrasonography. The tumor was found to have marked hypervascularity with contrast-enhanced computed tomography (CT) and magnetic resonance. Combined ¹⁸F-fluorodeoxyglucose positron emission tomography and CT (¹⁸F-FDG PET/CT) showed ¹⁸F-FDG by the tumor with a maximal standardized uptake value of 2.98 at 50 min and 3.29 at 100 min following injection of ¹⁸F-FDG. ¹⁸F-FDG PET/CT suggested no extrapancreatic spread of the tumor. The patient had no pancreatic hormone-associated symptoms. Distal pancreatectomy was performed, and a well-differentiated endocrine tumor was diagnosed. The resected specimen showed neither infiltration of adjacent structures nor metastasis to regional lymph nodes. The present case suggests that ¹⁸F-FDG PET/CT is a reliable modality for staging endocrine pancreatic tumors.     

Pseudomesotheliomatous lung cancer mimicking mesothelioma on 18F-FDG PET/CT images: report of 2 cases

The authors report two cases of pseudomesotheliomatous lung cancer (PLC) detected by ¹⁸F-FDG PET/CT scan. ¹⁸F-FDG PET/CT clearly revealed the extent of the disease in both cases, a case of adenocarcinoma of the lung and a case of squamous cell carcinoma of the lung. Intense ¹⁸F-FDG uptake by the diffusely thickened pleurae and primary lesion was observed in both cases, and increased ¹⁸F-FDG uptake by a pelvic bone metastasis was observed in the case of squamous cell carcinoma. Although PLC is indistinguishable from malignant pleural mesothelioma on ¹⁸F-FDG PET/CT scans, ¹⁸F-FDG PET/CT was helpful in identifying the primary focus of the PLCs and in staging the disease. Diagnostic image interpreters should be familiar with the ¹⁸F-FDG PET/CT findings in PLC.     

<Superscript>68</Superscript>Gallium-Arginine-Glycine-Aspartic Acid and <Superscript>18</Superscript>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull

We report the case of a 32 year-old male with Chondroblastic Osteosarcoma of the skull, which was imaged with both ¹⁸[F]fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) and ⁶⁸Gallium-arginine-glycine-aspartic acid (⁶⁸Ga-RGD) PET/CT. The ¹⁸F-FDG PET/CT did not demonstrate the tumour, whereas the ⁶⁸Ga-RGD PET/CT clearly depicted a left-sided frontal tumour. ⁶⁸Ga-RGD PET/CT may be a clinically useful imaging modality for early detection of recurrent osteosarcoma, considering the limitations of ¹⁸F-FDG PET in a setting of low glycolytic activity.     

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results

Purpose Multiple myeloma (MM) is a malignant B cell and plasma cell disorder which involves the skeleton in more than 80% of patients at diagnosis. The aim of this study was to compare whole-body X-ray (WBXR), MRI and ¹⁸F-FDG PET/CT in patients with MM. Methods The study population comprised 28 newly diagnosed MM patients. Findings of ¹⁸F-FDG PET/CT were compared with those of WBXR and MRI with regard to the number and site of lesions detected. Results Comparing ¹⁸F-FDG PET/CT and WBXR, it was found that in 16/28 pts (57%) ¹⁸F-FDG PET/CT detected more lesions, all of which were located in the skeleton. Nine of these 16 patients had a completely negative WBXR survey. In 12/28 pts (43%) the two methods yielded equivalent findings. Comparing ¹⁸F-FDG PET/CT and MRI, it was found that in 7/28 pts (25%), ¹⁸F-FDG PET/CT detected more lytic bone lesions, all of which were located outside the field of view of MRI (bone lesions in six cases and a soft tissue lesion in one). In 14/28 pts (50%), ¹⁸F-FDG PET/CT and MRI detected the same number of lesions in the spine and pelvis, while in 7/28 pts (25%) MRI detected an infiltrative pattern in the spine whereas ¹⁸F-FDG PET/CT was negative. Conclusion ¹⁸F-FDG PET/CT appears to be more sensitive than WBXR for the detection of small lytic bone lesions, whereas it has the same sensitivity as MRI in detecting bone disease of the spine and pelvis. On the other hand, MRI may be superior to ¹⁸F-FDG PET/CT in diagnosing an infiltrative pattern in the spine. Therefore, careful evaluation of MM bone disease at diagnosis should include both MRI of the spine and ¹⁸F-FDG PET/CT.     

Primary Renal Leiomyosarcoma Presenting with Subcutaneous and Osseous Metastases: Staging and Follow-Up with 18F-FDG PET/CT

A 60 year old woman who presented with multiple small subcutaneous nodules in the upper back and arms, was referred for an [18F] fluoro-2-deoxy-D-glucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) after histological evaluation revealed metastatic leiomyosarcoma of unknown origin. The PET/CT showed multiple ¹⁸F-FDG-avid subcutaneous nodules, bone lesions, as well as a large left renal mass, which was biopsied to confirm a primary renal leiomyosarcoma arising from the renal parenchyma. A post therapy PET/CT showed overall progression of disease. The use of ¹⁸F-FDG PET/CT in the staging and evaluation of response to therapy of a renal leiomyosarcoma has not been previously described in the literature.     

Late Port Site Metastasis from Occult Gall Bladder Carcinoma After Laparoscopic Cholecystectomy for Cholelithiasis: The Role of 18F-FDG PET/CT

Late port site metastasis of gall bladder carcinoma (GBC) after laparoscopic cholecystectomy is a rare finding. Rarer still is such a presentation where the GBC remained occult at histopathology. ¹⁸F-flurodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) can play an important role in this setting by supporting the diagnosis of port site metastasis, by demonstrating additional sites of metastasis, if any, and by ruling out any other primary site. We here present two such patients with late port site metastasis of occult GBC after laparoscopic cholecystectomy for cholelithiasis and discuss the role of ¹⁸F-FDG PET/CT in this setting.     

<Superscript>18</Superscript>F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma

Purpose Uterine carcinosarcomas clinically confined to the uterus usually harbor occult metastases. We conducted a pilot study to evaluate the value of ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in uterine carcinosarcoma. Methods Patients with histologically confirmed uterine carcinosarcoma were enrolled. Abdominal and pelvic magnetic resonance imaging (MRI)/whole-body computed tomography (CT) scan, and whole-body ¹⁸F-FDG PET or PET/CT were undertaken for primary staging, evaluating response, and restaging/post-therapy surveillance. The clinical impact of ¹⁸F-FDG PET was determined on a scan basis. Results A total of 19 patients were recruited and 31 ¹⁸F-FDG PET scans (including 8 scans performed on a PET/CT scanner) were performed. Positive impacts of scans were found in 36.8% (7/19) for primary staging, 66.7% (2/3) for monitoring response, and 11.1% (1/9) for restaging/post-therapy surveillance. PET excluded falsely inoperable disease defined by MRI in two patients. Aggressive treatment applying to three patients with PET-defined resectable stage IVB disease seemed futile. Two patients died of disease shortly after salvage therapy restaged by PET. With PET monitoring, one stage IVB patient treated by targeted therapy only was alive with good performance. Using PET did not lead to improvement of overall survival of this series compared with the historical control (n = 35) (P = 0.779). Conclusions The preliminary results suggest that ¹⁸F-FDG PET is beneficial in excluding falsely inoperable disease for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment under the guidance of PET. PET seems to have limited value in post-therapy surveillance or restaging after failure.